Because IFN-γ is a major product of Th1 cells [43], these results suggest that DXM may be effective in several Th1-dominant chronic inflammatory diseases, such as multiple sclerosis (MS), diabetes, and rheumatoid arthritis (RA) [44]. The gene discussed is IFNG; the disease is myeloid sarcoma.